共 29 条
[1]
Guan H(2019)Cost-effectiveness of alectinib for patients with untreated ALK-positive non-small cell lung cancer in China Adv Ther 36 1114-1125
[2]
Sheng Y(2017)Extrapolation of survival curves from cancer trials using external information Med Decis Mak 37 353-366
[3]
Guo W(2016)When simple becomes complicated: why excel should lose its place at the top table. global & regional health technology assessment: Italian; Northern Europe and Spanish SAGE J 7 4993-5005
[4]
Han S(2017)410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK + non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study Ann Oncol 13 203-226
[5]
Shi L(2018)The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: a network meta-analysis Cancer Med undefined undefined-undefined
[6]
Guyot P(2004)Comprehensive decision analytical modelling in economic evaluation: a Bayesian approach Health Econ undefined undefined-undefined
[7]
Ades AE(undefined)undefined undefined undefined undefined-undefined
[8]
Beasley M(undefined)undefined undefined undefined undefined-undefined
[9]
Lueza B(undefined)undefined undefined undefined undefined-undefined
[10]
Pignon JP(undefined)undefined undefined undefined undefined-undefined